PAION AG / Key word(s): Research Update
11.04.2016 20:54
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
PAION SUCCESSFULLY COMPLETES PATIENT RECRUITMENT IN PHASE III STUDY WITH
REMIMAZOLAM FOR PROCEDURAL SEDATION DURING COLONOSCOPY
- No safety concerns
- Headline data expected in mid 2016
Aachen (Germany), 11 April 2016 - The Specialty Pharma Company PAION AG
(ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) announces
today's successful completion of recruitment in the U.S. Phase III clinical
trial of Remimazolam, an ultra-short-acting sedative/anesthetic, for
procedural sedation in patients undergoing colonoscopy. No drug-related
serious adverse event has been reported.
This Phase III clinical trial - conducted at multiple sites throughout the
U.S. - was a prospective, double-blind, randomized, midazolam- and
placebo-controlled study in 460 patients undergoing colonoscopies for
diagnostic or therapeutic reasons. Patients were randomized to receive
either Remimazolam or midazolam or placebo in addition to fentanyl in order
to achieve adequate sedation to start and perform the procedure. In this
study short-term procedural sedation with Remimazolam in comparison to the
use of midazolam and placebo was investigated. The primary endpoint was
defined as successful completion of the colonoscopy procedure with no
requirement for alternative sedatives as compared to placebo plus fentanyl.
Non-responders to placebo received midazolam at doses being used according
to current local medical practice. The midazolam study arm was added to
compare efficacy against the labelled midazolam dose including onset/offset
times. It also served as an additional safety reference.
Headline data are expected mid 2016.
###
PAION Contact
Ralf Penner
Director Investor Relations / Public Relations
PAION AG
Martinstrasse 10-12
52062 Aachen - Germany
Phone: +49 241 4453-152
E-mail: r.penner@paion.com
www.paion.com
Disclaimer:
This release contains certain forward-looking statements concerning the
future business of PAION AG. These forward-looking statements contained
herein are based on the current expectations, estimates and projections of
PAION AG's management as of the date of this release. They are subject to a
number of assumptions and involve known and unknown risks, uncertainties
and other factors. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ materially from any
future results and developments expressed or implied by such
forward-looking statements. Considering the risks, uncertainties and other
factors involved, recipients should not rely unreasonably upon these
forward-looking statements. PAION AG has no obligation to periodically
update any such forward-looking statements to reflect future events or
developments.
11.04.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: PAION AG
Martinstr. 10-12
52062 Aachen
Germany
Phone: +49 (0)241-4453-0
Fax: +49 (0)241-4453-100
E-mail: info@paion.com
Internet: www.paion.com
ISIN: DE000A0B65S3
WKN: A0B65S
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-Adhoc: PAION SUCCESSFULLY COMPLETES PATIENT RECRUITMENT IN PHASE III STUDY WITH REMIMAZOLAM FOR PROCEDURAL SEDATION DURING COLONOSCOPY
| Quelle: EQS Group AG